2. Search Result
Search Result
Results for "

chronic+constipation

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

4

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17584
    Linaclotide
    2 Publications Verification

    		 Guanylate Cyclase Cancer
    Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
    Linaclotide
  • HY-17638
    Mizagliflozin
    5 Publications Verification

    DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base

    		 SGLT Metabolic Disease
    Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .
    Mizagliflozin
  • HY-14151
    Prucalopride
    4 Publications Verification

    		 5-HT Receptor Apoptosis Autophagy Neurological Disease Cancer
    Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride
  • HY-B0679
    Lubiprostone
    1 Publications Verification

    RU-0211; SPI-0211

    		 Chloride Channel CFTR Glutathione Peroxidase NO Synthase TNF Receptor Metabolic Disease
    Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research .
    Lubiprostone
  • HY-12694
    Prucalopride succinate
    4 Publications Verification

    R-108512

    		 5-HT Receptor Apoptosis Autophagy Metabolic Disease Cancer
    Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride succinate
  • HY-N7104
    Lactitol

    D-Lactitol

    		 Bacterial Infection Neurological Disease Endocrinology
    Lactitol (D-Lactitol) is a non-absorbable disaccharide and Bacterial regulator. Lactitol reduces the populations of Bacteroides, Clostridium, coliforms and Eubacterium, while increasing the populations of Lactobacillus and Streptococcus. Lactitol can be used in the research of portosystemic encephalopathy and chronic constipation .
    Lactitol
  • HY-B1389
    Lactitol monohydrate

    D-Lactitol monohydrate

    		 Bacterial Infection Neurological Disease Endocrinology
    Lactitol monohydrate (D-Lactitol monohydrate) is a non-absorbable disaccharide and Bacterial regulator. Lactitol monohydrate reduces the populations of Bacteroides, Clostridium, coliforms and Eubacterium, while increasing the populations of Lactobacillus and Streptococcus. Lactitol monohydrate can be used in the research of portosystemic encephalopathy and chronic constipation .
    Lactitol monohydrate
  • HY-17584A
    Linaclotide acetate
    2 Publications Verification

    		 Guanylate Cyclase Cancer
    Linaclotide acetate is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
    Linaclotide acetate
  • HY-B0680
    Lubiprostone (hemiketal)

    RU-0211 (hemiketal); SPI-0211 (hemiketal)

    		 Chloride Channel Others Cancer
    Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .
    Lubiprostone (hemiketal)
  • HY-144401
    DS-3801b
    1 Publications Verification

    		 Motilin Receptor Metabolic Disease
    DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation .
    DS-3801b
  • HY-17584R
    Linaclotide (Standard)

    		Reference Standards Guanylate Cyclase Cancer
    Linaclotide (Standard) is the analytical standard of Linaclotide. This product is intended for research and analytical applications. Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
    Linaclotide (Standard)
  • HY-12694R
    Prucalopride succinate (Standard)

    R-108512 (Standard)

    		 5-HT Receptor Apoptosis Autophagy Reference Standards Metabolic Disease Cancer
    Prucalopride (succinate) (Standard) is the analytical standard of Prucalopride (succinate). This product is intended for research and analytical applications. Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride succinate (Standard)
  • HY-P11246
    A13:B7-24-GG

    		RXFP Receptor Metabolic Disease
    A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
    A13:B7-24-GG
  • HY-N7104R
    Lactitol (Standard)

    D-Lactitol (Standard)

    		 Reference Standards Bacterial Infection Neurological Disease Metabolic Disease Endocrinology
    Lactitol (Standard) is the analytical standard of Lactitol (HY-N7104). This product is intended for research and analytical applications. Lactitol (D-Lactitol) is a non-absorbable disaccharide and Bacterial regulator. Lactitol reduces the populations of Bacteroides, Clostridium, coliforms and Eubacterium, while increasing the populations of Lactobacillus and Streptococcus. Lactitol can be used in the research of portosystemic encephalopathy and chronic constipation .
    Lactitol (Standard)
  • HY-B1389R
    Lactitol monohydrate (Standard)

    D-Lactitol monohydrate (Standard)

    		 Reference Standards Bacterial Infection Neurological Disease Endocrinology
    Lactitol (monohydrate) (Standard) is the analytical standard of Lactitol monohydrate (HY-B1389). This product is intended for research and analytical applications. Lactitol monohydrate (D-Lactitol monohydrate) is a non-absorbable disaccharide and Bacterial regulator. Lactitol monohydrate reduces the populations of Bacteroides, Clostridium, coliforms and Eubacterium, while increasing the populations of Lactobacillus and Streptococcus. Lactitol monohydrate can be used in the research of portosystemic encephalopathy and chronic constipation .
    Lactitol monohydrate (Standard)
  • HY-B0679R
    Lubiprostone (Standard)

    RU-0211 (Standard); SPI-0211 (Standard)

    		 Reference Standards Chloride Channel CFTR Glutathione Peroxidase NO Synthase TNF Receptor Metabolic Disease
    Lubiprostone (Standard) is the analytical standard of Lubiprostone. This product is intended for research and analytical applications. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research .
    Lubiprostone (Standard)
  • HY-B0679S
    Lubiprostone-d7

    RU-0211-d7; SPI-0211-d7

    		 Isotope-Labeled Compounds Chloride Channel CFTR Glutathione Peroxidase NO Synthase TNF Receptor Metabolic Disease
    Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research .
    Lubiprostone-d7
  • HY-14152
    Prucalopride hydrochloride

    		5-HT Receptor Cancer
    Prucalopride hydrochloride is an orally active, selective and specific 5-HT4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride hydrochloride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride hydrochloride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride hydrochloride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride hydrochloride
  • HY-14151R
    Prucalopride (Standard)

    		Reference Standards 5-HT Receptor Apoptosis Autophagy Neurological Disease Cancer
    Prucalopride (Standard) is the analytical standard of Prucalopride. This product is intended for research and analytical applications. Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .
    Prucalopride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: